Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.63 |
| ▸ | PPARA | Q07869 | 17/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 15/20 | 0.63 |
| ▸ | PTGES | O14684 | 13/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL7465088 | 0.88 | PPARG (0.63) | PPARGPPARAALOX5PTGESMMP9 | |
| SCHEMBL6935114 | 0.88 | PPARG (0.65) | PPARGPPARAALOX5PTGESMMP9 | |
| SCHEMBL6930527 | 0.86 | PPARG (0.67) | PPARGPPARAALOX5PTGES | |
| SCHEMBL9099026 | 0.83 | PPARG (0.64) | PPARGPPARAALOX5PTGES | |
| SCHEMBL8356987 | 0.83 | PPARG (0.64) | PPARGPPARAALOX5PTGES | |
| SCHEMBL9099036 | 0.83 | PPARG (0.64) | PPARGPPARAALOX5PTGES | |
| SCHEMBL22612343 | 0.83 | PPARG (0.64) | PPARGPPARAALOX5PTGES | |
| SCHEMBL6935204 | 0.82 | PPARG (0.56) | PPARGPPARAALOX5PTGES | |
| SCHEMBL7345917 | 0.82 | PPARG (0.72) | PPARGPPARAALOX5PTGES | |
| SCHEMBL5081085 | 0.81 | PPARG (0.66) | PPARGPPARAALOX5PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6462073-B2 | METALLOPROTEASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | PPARG 1660/4885PPARA 1386/4885ALOX5 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.